Brief: Actuate Announces FDA Rare Pediatric Disease Designation Granted To Elraglusib For Treatment Of Ewing Sarcoma
12/11/2024 13:20
Nov 12 (Reuters) - Actuate Therapeutics Inc ACTU.O :
* ACTUATE ANNOUNCES FDA RARE PEDIATRIC DISEASE DESIGNATION
GRANTED
TO ELRAGLUSIB FOR TREATMENT OF EWING SARCOMA
* ACTUATE THERAPEUTICS INC - TOPLINE PHASE 1 DATA FOR
ELRAGLUSIB
EXPECTED IN 2H 2025
Source text: ID:nGNXc0gGtT
Further company coverage: ACTU.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Actuate Therapeutics
See all newsHealth Rounds: Actuate Therapeutics drug improves survival odds in pancreatic cancer trial
Brief: Actuate Therapeutics Announces Plans To Expand Clinical Pipeline, Advancing Elraglusib Tablet Into A Phase 1/2 Clinical Program In Refractory Cancers
Brief: Actuate Therapeutics Inc - Reports Positive Phase 2 Trial Data For Elraglusib - SEC Filing
Brief: Actuate Therapeutics Announces Positive Patient Outcomes From Phase 1 Trial
Brief: Actuate Therapeutics Inc - Enters At The Market Issuance Sales Agreement With B. Riley And Craig-Hallum - SEC Filing